TICKERNOMICS Sign up
Last Update: 2023-10-04 11:37:12
Allena Pharmaceuticals Inc ( ALNA ) https://www.allenapharma.com
0.01USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
14.73%
-37.78%
ALNA
SPY
36.71%
-99.26%
ALNA
SPY
70.96%
-99.89%
ALNA
SPY
262.36%
ALNA
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1.13
-5.46
0.17
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.04
2.68
0.30
-131.76
0.00
0.00
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-13118.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.3921
-198.84
-209.31
-0.09
Other Earnings and Cash Flow Stats:
Allena Pharmaceuticals Inc ( ALNA ) Net Income TTM ($MM) is -29.64
Allena Pharmaceuticals Inc ( ALNA ) Operating Income TTM ($MM) is -43.16
Allena Pharmaceuticals Inc ( ALNA ) Owners' Earnings Annual ($MM) is -51.08
Allena Pharmaceuticals Inc ( ALNA ) Current Price to Owners' Earnings ratio is -0.50
Allena Pharmaceuticals Inc ( ALNA ) EBITDA TTM ($MM) is -42.75
Allena Pharmaceuticals Inc ( ALNA ) EBITDA Margin is 0.00%
Capital Allocation:
Allena Pharmaceuticals Inc ( ALNA ) has paid 0.00 dividends per share and bought back 0.0 million shares in the past 12 months
Allena Pharmaceuticals Inc ( ALNA ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
Allena Pharmaceuticals Inc ( ALNA ) Interest-bearing Debt ($MM) as of last quarter is 0
Allena Pharmaceuticals Inc ( ALNA ) Annual Working Capital Investments ($MM) are -10
Allena Pharmaceuticals Inc ( ALNA ) Book Value ($MM) as of last quarter is 3
Allena Pharmaceuticals Inc ( ALNA ) Debt/Capital as of last quarter is 2%
Other Balance Sheet Stats:
Allena Pharmaceuticals Inc ( ALNA ) has 6 million in cash on hand as of last quarter
Allena Pharmaceuticals Inc ( ALNA ) has 10 million of liabilities due within 12 months, and long term debt 14 as of last quarter
Allena Pharmaceuticals Inc ( ALNA ) has 100 common shares outstanding as of last quarter
Allena Pharmaceuticals Inc ( ALNA ) has 95 million USD of preferred stock value
Academic Scores:
Allena Pharmaceuticals Inc ( ALNA ) Altman Z-Score is 0.00 as of last quarter
Allena Pharmaceuticals Inc ( ALNA ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Allena Pharmaceuticals Inc ( ALNA ) largest shareholder is 1620 Investment Advisors Inc owning 15000 shares at 0.00 ($MM) value
Katz Richard D(Chief Financial Officer) Bought 255000 shares of Allena Pharmaceuticals Inc ( ALNA ) for the amount of $0.00 on 2022-02-01
1.02% of Allena Pharmaceuticals Inc ( ALNA ) is held by insiders, and 7.42% is held by institutions
Allena Pharmaceuticals Inc ( ALNA ) went public on 2017-11-02
Other Allena Pharmaceuticals Inc ( ALNA ) financial metrics:
FCF:-40.47
Unlevered Free Cash Flow:-18.63
EPS:-0.38
Operating Margin:-13118.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-901.90
Beta:-0.09
Buffet's Owners Earnings:-51.08
Price to Owner's Earnings:-0.50
About Allena Pharmaceuticals Inc ( ALNA ) :
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.